Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · IEX Real-Time Price · USD
1.720
+0.040 (2.38%)
At close: Jul 26, 2024, 3:59 PM
1.710
-0.010 (-0.58%)
After-hours: Jul 26, 2024, 5:19 PM EDT
Cyclacel Pharmaceuticals Revenue
Cyclacel Pharmaceuticals had revenue of $29.00K in the quarter ending March 31, 2024. This brings the company's revenue in the last twelve months to $449.00K. In the year 2023, Cyclacel Pharmaceuticals had annual revenue of $420.00K.
Revenue (ttm)
$449.00K
Revenue Growth
n/a
P/S Ratio
5.54
Revenue / Employee
$37,417
Employees
12
Market Cap
2.49M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
cbdMD | 21.58M |
InMed Pharmaceuticals | 5.63M |
Tenon Medical | 3.21M |
Helius Medical Technologies | 668.00K |
FOXO Technologies | 139.00K |
Aclarion | 60.05K |
Heart Test Laboratories | 18.60K |
CYCC News
- 4 weeks ago - Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions - GlobeNewsWire
- 7 weeks ago - Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire